Astria Therapeutics, Inc. (NASDAQ:ATXS) Receives $30.00 Average PT from Analysts

Shares of Astria Therapeutics, Inc. (NASDAQ:ATXSGet Free Report) have earned a consensus recommendation of “Buy” from the eight brokerages that are covering the company, Marketbeat Ratings reports. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $30.00.

A number of equities research analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a research report on Friday. Wedbush reissued an “outperform” rating and set a $28.00 price objective (up previously from $27.00) on shares of Astria Therapeutics in a report on Wednesday, March 12th. Finally, Cantor Fitzgerald reissued an “overweight” rating and set a $47.00 price objective on shares of Astria Therapeutics in a report on Wednesday, May 14th.

View Our Latest Stock Analysis on Astria Therapeutics

Astria Therapeutics Stock Up 2.1%

Shares of Astria Therapeutics stock opened at $5.72 on Thursday. The stock has a market capitalization of $322.80 million, a P/E ratio of -2.74 and a beta of 0.39. The company has a 50-day simple moving average of $4.61 and a 200 day simple moving average of $6.57. Astria Therapeutics has a 12-month low of $3.56 and a 12-month high of $12.92.

Astria Therapeutics (NASDAQ:ATXSGet Free Report) last announced its earnings results on Tuesday, May 13th. The biotechnology company reported ($0.58) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.10). On average, equities analysts anticipate that Astria Therapeutics will post -1.65 earnings per share for the current year.

Institutional Investors Weigh In On Astria Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS bought a new position in shares of Astria Therapeutics in the 4th quarter valued at about $41,000. GAMMA Investing LLC boosted its stake in shares of Astria Therapeutics by 1,127.4% in the 1st quarter. GAMMA Investing LLC now owns 8,678 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,971 shares during the last quarter. Brooklyn Investment Group boosted its stake in shares of Astria Therapeutics by 1,079.6% in the 1st quarter. Brooklyn Investment Group now owns 8,694 shares of the biotechnology company’s stock valued at $46,000 after purchasing an additional 7,957 shares during the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Astria Therapeutics by 109.2% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,299 shares of the biotechnology company’s stock valued at $47,000 after purchasing an additional 2,766 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Astria Therapeutics in the 4th quarter valued at about $50,000. Institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

(Get Free Report

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.

Featured Stories

Analyst Recommendations for Astria Therapeutics (NASDAQ:ATXS)

Receive News & Ratings for Astria Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astria Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.